In patients with systemic lupus erythematosus, impaired upper limb function and difficulty performing daily activities are linked to various quality-of-life domains.

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

An international team, led by Paul R. Fortin of Université Laval, has just identified three markers that would allow for establishing, right at the time of diagnosis, the risk of a lupus ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...